Evidence map›Paper›PMID 37629169›Full record

ArticleInternational journal of molecular sciences2023

ATRX Loss in the Development and Prognosis of Conjunctival Melanoma.

Jolique A van Ipenburg, Quincy C C van den Bosch, Dion Paridaens, Hendrikus J Dubbink, Emine Kiliç, Nicole Naus, Robert M Verdijk, Rotterdam Ocular Melanoma Study Group

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jolique A van IpenburgDepartment of Pathology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Quincy C C van den BoschDepartment of Ophthalmology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Dion ParidaensDepartment of Ophthalmology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-6762-3614
Hendrikus J DubbinkDepartment of Pathology, Section Ophthalmic Pathology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-2160-5207
Emine KiliçDepartment of Ophthalmology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Nicole NausDepartment of Ophthalmology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Robert M VerdijkDepartment of Ocular Oncology, The Rotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.ORCID 0000-0003-1437-214X
Rotterdam Ocular Melanoma Study Group
Erasmus MC · NLLeiden University Medical Center · NLRadboud University Nijmegen · NL

Funding

Stichting Nederlands Oogheelkundig Onderzoek (SNOO). Stichting Wetenschappelijk Oogheelkundig Onderzoek (SWO). Grant no: 2013-2021, Grant no: 2016- 2017
6 · The paper itself

Abstract

Metastatic disease is linked to

Indexed as

Bone NeoplasmsConjunctival NeoplasmsMelanomaSkin NeoplasmsHumansMelanocytesX-linked Nuclear ProteinATRX protein, humanX-linked Nuclear Proteinconjunctival melanomageneticspathology

Identifiers

PMID37629169
PMCPMC10454703
OpenAlexW4386030063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.